|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Comparison of esophageal capsule endoscopy and esophagogastroduodenoscopy for diagnosis of esophageal varices显示文摘AIM: To investigate the utility of esophageal capsule endoscopy in the diagnosis and grading of esophageal varices. METHODS: Cirrhotic patients who were undergo-ing esophagogastroduodenoscopy (EGD) for variceal screening or surveillance underwent capsule endos-copy. Two separate blinded investigators read each capsule endoscopy for the following results: variceal grade, need for treatment with variceal banding or prophylaxis with beta-blocker therapy, degree of portal hypertensive gastropathy, and gastric varices. RESULTS: Fifty patients underwent both capsule and EGD. Forty-eight patients had both procedures on the same day, and 2 patients had capsule endoscopy within 72 h of EGD. The accuracy of capsule endos- copy to decide on the need for prophylaxis was 74%, with sensitivity of 63% and specificity of 82%. Inter-rater agreement was moderate (kappa = 0.56). Agree-ment between EGD and capsule endoscopy on grade of varices was 0.53 (moderate). Inter-rater reliability was good (kappa = 0.77). In diagnosis of portal hyper-tensive gastropathy, accuracy was 57%, with sensitiv-ity of 96% and specificity of 17%. Two patients had gastric varices seen on EGD, one of which was seen on capsule endoscopy. There were no complications from capsule endoscopy.CONCLUSION: We conclude that capsule endoscopy has a limited role in deciding which patients would benefit from EGD with banding or beta-blocker thera-py. More data is needed to assess accuracy for staging esophageal varices, PHG, and the detection of gastric varices. | Catherine T Frenette John G Kuldau Donald J Hillebrand Jill Lane Paul J Pockros | 2008 | World Journal of Gastroenterology2008，14，28： | 7 |
| 2 | Pulmonary complications of transcatheter arterial chemoembolization for hepatocellular carcinoma显示文摘Transcatheter arterial chemoembolization(TACE) is an effective palliative intervention that is widely accepted for the management of hepatocellular carcinoma(HCC). Post-TACE pulmonary complications resulting in acute lung injury(ALI) or acute respiratory distress syndrome(ARDS) are rare events. Pulmonary complications after TACE are thought to be related to chemical injury subsequent to the migration of the infused ethiodized oil or chemotherapeutic agent to the lung vasculature, facilitated by arteriovenous(AV) shunts within the hyper-vascular HCC. We review herein the literature on pulmonary complications related to TACE for HCC. Post-TACE pulmonary complications have included pulmonary oil embolism, interstitial pneumonitis, chemical pneumonitis, ALI, ARDS, lipoid pneumonia, acute eosinophilic and neutrophilic pneumonia, bilious pleuritis, pulmonary abscess, pulmonary tumor embolism, and possibly pulmonary metastasis with HCC. The risk factors associated with post-TACE pulmonary complications identified in the literature include large hyper-vascular HCC with AV shunts, large-volume Lipiodol infusion, and embolization via the right inferior phrenic artery. However, the absence of known risk factors is not a guarantee against serious complications. An astute awareness of the potential post-TACE pulmonary complications should expedite appropriate therapeutic interventions and increase potential for early recovery. | Quan M Nhu Harry Knowles Paul J Pockros Catherine T Frenette | 2016 | World Journal of Respirology2016，6，3： | 4 |
| 3 | Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure显示文摘 | Stanislas Pol Jeroen Aerssens Stefan Zeuzem Pietro Andreone Eric J. Lawitz Stuart Roberts Zobair Younossi Graham R. Foster Roberto Focaccia Andrzej Horban Paul J. Pockros Rolf P.G. Van Heeswijk Sandra De Meyer Don Luo Martyn Botfield Maria Beumont Gaston | 2013 | Journal of Hepatology2013，，5： | 2 |
| 4 | GI-5005 therapeuticvaccine plus peg-IFN/ribavirin improves sustained virologicresponse virus peg-IFN/ribavirin in prior non-responders withgenotype 1 chronic HCY infection 显示文摘 | Pockros P Jacobson I Boyer TD | 2010 | Hepatology2010，52，： | 1 |
| 5 | Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction显示文摘 | Geraldine M. Ferron Richard A. Preston Robert J. Noveck Paul Pockros Philip Mayer John Getsy Marybeth Turner Madelyn Abell Jeffrey Paul | 2001 | Clinical Therapeutics2001，，8： | 1 |
| 6 | HCV RNA viral load assessments in the era of direct-acting antivirals 显示文摘 | Cobb B Pockros PJ Vilchez RA | 2013 | Am J Gastroenterol2013，108，4： | 1 |
| 7 | Efficacy and safety of pegylated (40 kd)interferon alpha-2a compared withinterferon alpha-2a in noncir- rhotie patientswith chronic hepatiffs C 显示文摘 | Reedy KR Wright TL Pockros PJ | 2001 | Hepatology2001，33，： | 1 |
| 8 | Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure显示文摘 | Stanislas Pol Jeroen Aerssens Stefan Zeuzem Pietro Andreone Eric J. Lawitz Stuart Roberts Zobair Younossi Graham R. Foster Roberto Focaccia Andrzej Horban Paul J. Pockros Rolf P.G. Van Heeswijk Sandra De Meyer Don Luo Martyn Botfield Maria Beumont Gaston | 2013 | Journal of Hepatology2013，，5： | 1 |
| 9 | HCV RNA viral load assessments in the era of direct-acting antivirals 显示文摘 | Cobb B Pockros PJ Vilchez RA | 2013 | Am J Gastroenterol2013，108，4： | 1 |
| 10 | HCV-RNA viral load assessments in the era of direct- acting antivirals显示文摘 | Cobb B Pockros PJ Vilchez RA | 2013 | Am J Gastroenterol2013，108，4： | 1 |
| 11 | Final results of a double- blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma lb in chronic hepatitis C patients with advanced fibrosis or cirrhosis 显示文摘 | Pockros PJ Jeffers L Afdhal N | 2007 | Hepatology2007，45，3： | 1 |
| 12 | Developments in the treatment of chronic hepatitis C 显示文摘 | Pockros Paul J | 2002 | Expert Opin Investig Drugs2002，11，4： | 1 |
| 13 | Impact of obesity on treatment of chronic hepatitis C显示文摘 | CHARLTON MR POCKROS P J HARRISON SA | 2006 | Hepatology2006，43，6： | 1 |
| 14 | Efficacy and safety ofpegylated (4-kd) interfreon alpha-2a compared with interferon alplla-2ain noncirrhotic patients with chronic hepatitis C显示文摘 | Reedy KR Wright TL Pockros PJ | 2001 | Hepatology2001，33，43： | 1 |
| 15 | Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C显示文摘 | K.Rajender Reddy Teresa L. Wright Paul J. Pockros Mitchell Shiffman Gregory Everson Robert Reindollar Michael W. Fried Preston P. Purdum Donald Jensen Coleman Smith William M. Lee Thomas D. Boyer Amy Lin Simon Pedder Jean DePamphilis | 2001 | Hepatology2001，，2： | 1 |
| 16 | Efficacy and safety of pegylated (40- kd) interferon alpha- 2a compared with interferon alpha- 2a in noncirrhotc patients with chronic hepatitis C显示文摘 | Wright TL Pockros PJ etal | 2001 | Hepatolgy2001，33，： | 1 |
| 17 | Developments in treatment of chronic hepatitis C显示文摘 | Pockros P J | 2002 | Exp Opin Invest Drugs2002，11，4： | 1 |
| 18 | Sustained virologic response rates with telaprevir by response after 4<ce:hsp sp='0.25'/>weeks of lead-in therapy in patients with prior treatment failure显示文摘 | Graham R. Foster Stefan Zeuzem Pietro Andreone Stanislas Pol Eric J. Lawitz Moises Diago Stuart Roberts Paul J. Pockros Zobair Younossi Isabelle Lonjon-Domanec Sandra De Meyer Don Luo Shelley George Maria Beumont Gaston Picchio | 2012 | Journal of Hepatology2012，，： | 1 |
| 19 | Efficacy and safety of pegylated (40-kd)inteferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C显示文摘 | Reedy KR Wright TL Pockros PJ | 2001 | Hepatology2001，33，2： | 1 |
| 20 | Peginterferon- a2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose 显示文摘 | Hadziyannis SJ Sette H Jr Morgan TR Balan V Diago M Marcellin P Ramadori G Bodenheimer H Jr Bernstein D Rizzetto M Zeuzem S Pockros PJ Lin A Ackrill AM PEGASYS International Study Group | 2004 | Ann Intern Med2004，140，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员